Literature DB >> 7379445

Prazosin kinetics and effectiveness in renal failure.

D T Lowenthal, D Hobbs, M B Affrime, T M Twomey, E W Martinez, G Onesti.   

Abstract

Single and repeated doses of prazosin were given to 17 hypertensive patients, 5 with normal renal function and 12 with impaired renal function. Blood for prazosin assay was drawn after a 1-mg single dose and after patients reached steady-state levels with their long-term maintenance dose. As blood was drawn blood pressure was recorded. Prazosin absorption was not altered in patients with impaired renal function, and there is no cumulation of the drug when given repeatedly to patients with impaired renal function. Elimination kinetics were virtually identical regardless of degree of renal function. Effect on blood pressure was significantly better at the dosage range of 3 to 8 mg/day than at higher doses of 9 to 20 mg/day. There does not appear to be a direct relationship between the peak plasma prazosin level and the nadir of antihypertensive response. This would seem to indicate that the drug leaves the plasma and goes to the vascular smooth muscle receptor site of action. There appears to be no impairment in prazosin elimination in patients with impaired renal function, and its effectiveness (with diuretic or dialysis) is optimum at 3 to 8 mg/day.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7379445     DOI: 10.1038/clpt.1980.110

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Neuropsychiatric complications related to use of prazosin in patients with renal failure.

Authors:  D K Chin; A K Ho; C Y Tse
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-22

Review 3.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 4.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

5.  A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure.

Authors:  N Lameire; J Gordts
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

7.  Utilization Pattern of Potentially Inappropriate Medications in Geriatric Patients in a Tertiary Care Hospital: A Retrospective Observational Study.

Authors:  Rajal Sudhir Narvekar; Nikhil Narayan Bhandare; Jonathan Joaquim Gouveia; Padma Narayan Bhandare
Journal:  J Clin Diagn Res       Date:  2017-04-01

8.  Identification of a prazosin metabolite and some preliminary data on its kinetics in hypertensive patients.

Authors:  V K Piotrovskii; N N Veiko; O S Ryabokon; S F Postolnikov; V I Metelitsa
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 10.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.